Also, no other synaptic biomarker beyond GAP-43 is currently available in close enough proximity to longitudinal tau-PET assessments in open-access datasets such as ADNI, which clearly limits the study of synaptic changes in tau spreading in AD. Here, MAPT is linked to Alzheimer disease.